Patient-Derived Organoids in Pancreatic Cancer Pharmacology: From Pharmacotyping Methodology to the AVATAR Phase III Trial and the Pharmacological Frontier
Drug Design, Development and Therapy · 2026-11 · Volume 20 · 1-14
DOI: 10.2147/dddt.s646519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2026-11. Verfasst von Fahad I Alsaikhan. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Alsaikhan, F. I. (2026). Patient-Derived Organoids in Pancreatic Cancer Pharmacology: From Pharmacotyping Methodology to the AVATAR Phase III Trial and the Pharmacological Frontier. Drug Design, Development and Therapy, Volume 20, 1-14. https://doi.org/10.2147/dddt.s646519
Vancouver
Alsaikhan FI. Patient-Derived Organoids in Pancreatic Cancer Pharmacology: From Pharmacotyping Methodology to the AVATAR Phase III Trial and the Pharmacological Frontier. Drug Design, Development and Therapy. 2026;Volume 20:1-14. doi:10.2147/dddt.s646519
BibTeX
@article{Alsaikhan2026,
author = {Alsaikhan, Fahad I},
title = {Patient-Derived Organoids in Pancreatic Cancer Pharmacology: From Pharmacotyping Methodology to the AVATAR Phase III Trial and the Pharmacological Frontier},
journal = {Drug Design, Development and Therapy},
year = {2026},
volume = {Volume 20},
pages = {1--14},
doi = {10.2147/dddt.s646519}
}
EUVIMED